Identification of a Novel, Oncogenic and Targetable TPR::ABL2 Fusion Gene in T‐Cell Acute Lymphoblastic Leukaemia

eJHaem 2026 Open access

Read full text
Authors: Elias Lagonik, Elyse C. Page, Laura N Eadie, Caitlin E Schutz, Jacqueline A. Rehn, Susan L. Heatley, Andrew S. Moore, Muirin Healy, Morag Whyte, Timothy P. Hughes, David T. Yeung, Deborah L. White
DOI: 10.1002/jha2.70255
Cited by: 1
References: 15

Abstract

ABSTRACT ABL2 rearrangements represent a subtype of acute lymphoblastic leukaemia (ALL) associated with poor prognosis and survival. This study reports a high‐risk T‐cell ALL (T‐ALL) case with a novel TPR::ABL2 gene fusion resulting from a chromosomal deletion. Overexpression of TPR::ABL2 in Ba/F3 cells promoted cytokine‐independent growth, demonstrating its oncogenic nature. Both primary patient and Ba/F3 cells carrying TPR::ABL2 exhibited kinase activation and sensitivity to tyrosine kinase inhibitors (TKIs). This study expands the repertoire of ABL2 fusions identified in ALL and supports the incorporation of TKIs into T‐ALL treatment regimens to improve outcomes for this subtype.

Fields of Study & Subjects

Acute Lymphoblastic Leukemia research Chronic Myeloid Leukemia Treatments Carcinogens and Genotoxicity Assessment

Publication details

Journal / source
eJHaem
Publisher
Wiley
Volume
7
Issue
2
Pages
e70255–e70255
Publication date
2 March 2026
Language
EN